Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Design Therapeutics Inc (NQ: DSGN )

7.930 -0.340 (-4.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 710,156
Open 8.250
Bid (Size) 7.930 (56)
Ask (Size) 7.940 (17)
Prev. Close 8.270
Today's Range 7.740 - 8.250
52wk Range 6.942 - 26.30
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Design Therapeutics, Inc. (NASDAQ:DSGN) Shareholder Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 01/19/2023 -- Design Therapeutics, Inc. is under investigation over potential securities laws violations. 
Via SBWire
DESIGN ALERT: Bragar Eagel & Squire, P.C. is Investigating Design Therapeutics, Inc. on Behalf of Design Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire

Performance

YTD
-18.83%
-18.83%
1 Month
-18.83%
-18.83%
3 Month
-49.23%
-49.23%
6 Month
-57.32%
-57.32%
1 Year
-37.26%
-37.26%

More News

Read More
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
$7.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
4 Analysts Have This to Say About Design Therapeutics
Via Benzinga
S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
Via Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher
Via Benzinga
Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
Dow Rises 150 Points; US Jobless Claims Increase To 230,000
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
From Design Therapeutics, Inc.
Via Globe NewsWire
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
Via Benzinga
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
From Design Therapeutics, Inc.
Via Globe NewsWire
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
From Design Therapeutics, Inc.
Via Globe NewsWire
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
Via Benzinga
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating
Via Benzinga
46 Biggest Movers From Yesterday
Via Benzinga
54 Biggest Movers From Yesterday
Via Benzinga
56 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Via Benzinga
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.